Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis
2018 · JAMA · 221 citations
https://doi.org/10.1001/jama.2018.6129
B
Bernt van den Blink
Laurens(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
76
Papers
3.5K
Citations
31
h-index
42
i10-index
Bernt van den Blink is an academic researcher from Laurens. The author has contributed to research in topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Sarcoidosis and Beryllium Toxicity Research & Medical Imaging and Pathology Studies. The author has an h-index of 31, co-authored 65 publications.
Papers by this author
worksZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
2023 · JAMA · 103 citations
https://doi.org/10.1001/jama.2023.5355
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
2019 · The Lancet Respiratory Medicine · 99 citations
https://doi.org/10.1016/s2213-2600(19)30172-9
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis
2013 · Pulmonary Pharmacology & Therapeutics · 98 citations
https://doi.org/10.1016/j.pupt.2013.01.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat